What is semaglutide?
Semaglutide is a synthetic analog of the human incretin hormone GLP-1. Endogenous GLP-1 is released from the L-cells of the intestine in response to food intake and exerts multiple glucose-dependent actions: it stimulates insulin secretion from pancreatic beta-cells, suppresses glucagon release from alpha-cells, slows gastric emptying, and promotes satiety in the central nervous system. However, native GLP-1 has a very short half-life of just 1-2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
Semaglutide is engineered for prolonged action. Its structure features a modification that increases its binding affinity to albumin, significantly reducing its renal clearance and making it resistant to DPP-4 degradation. This results in a half-life of approximately one week, allowing for once-weekly subcutaneous administration.
The Efficacy of Semaglutide：
The clinical efficacy of semaglutide is well-established through large-scale, randomized controlled trials.
1.Glycemic Control in Type 2 Diabetes: In patients with type 2 diabetes, semaglutide demonstrates powerful HbA1c-lowering effects, typically ranging from 1.5% to 2.0%. Its glucose-dependent mechanism of action confers a low risk of hypoglycemia when used without insulin or insulin secretagogues. The slowed gastric emptying also helps in reducing postprandial glucose excursions.
2.Weight Management: Semaglutide's effects on weight loss are profound. By acting on appetite centers in the brain (specifically the hypothalamus), it reduces hunger and calorie intake. Clinical trials for chronic weight management have shown an average weight reduction of 15-20% of body weight over 68 weeks, establishing it as one of the most effective anti-obesity pharmacotherapies available.
3.Cardiovascular Benefits: Semaglutide has demonstrated significant cardiovascular (CV) benefits. The SUSTAIN-6 and PIONEER-6 trials showed that semaglutide reduces the risk of major adverse cardiovascular events (MACE)-a composite of CV death, non-fatal myocardial infarction, and non-fatal stroke-in patients with type 2 diabetes who have established cardiovascular disease or are at high CV risk.
4.Renal Outcomes: Emerging evidence from post-hoc analyses and dedicated trials like FLOW indicates that semaglutide may also have renoprotective effects, slowing the progression of diabetic kidney disease by reducing albuminuria and delaying the decline in estimated glomerular filtration rate (eGFR).
Who is a Suitable Candidate for Semaglutide?
The suitability for semaglutide depends on the specific indication and patient profile.
1.For Type 2 Diabetes Mellitus: It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is particularly suitable for:
- Patients who have not achieved glycemic targets with metformin and/or other oral agents.
- Those who would benefit from weight loss.
- Patients with established cardiovascular disease, where its cardioprotective effects are a major advantage.
2.For Chronic Weight Management: It is approved for chronic weight management in adults with:
- A body mass index (BMI) of 30 kg/m² or greater (obesity), or
- A BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia).
How to get semaglutide?
You can contact us. sales8@bpandabio.com or click here : semaglutide
MOQ:1 BOX(10vials/box)
Specification: 5mg/10mg/20mg/30mg/40mg/60mg
